Email ID
Password
Scrip   
Filing marks milestone for Eisai's oncology R&D
27 July 2009
Ian Haydock

Eisai has made an approval filing in Switzerland for its novel anticancer agent eribulin mesylate (E7389), marking the first submission for an oncology agent developed in-house by the Japanese firm.

The filing is for the use of the injectable product in locally advanced and metastatic disease,...



Please Login to read the full article.
JOB OF THE WEEK Promote your vacancy here
© 2010 Informa plc. All rights reserved.
This site is owned and operated by Informa plc ("Informa") whose registered office is Mortimer House, 37-41 Mortimer Street, London, W1T 3JH. Registered in England and Wales. Number 3099067. UK VAT Group: GB 365 4626 36